## Supplementary Figure legends.

**Figure S 1.** Enlarged immunostaining image of U87 cells show decrease and change of Y397-FAK and FAK localization in Y15-treated compared with untreated cells. Upper panel: Merged images from Fig 3B with Y397-FAK (left panels) and FAK staining (right panels) in U87 cells are shown with the boxed areas marked by white rectangles, which are enlarged and included on the lower panels. The arrows show Y397-FAK and FAK localization at the focal adhesions and filopodia in untreated U87 cells and arrowheads show the protein localization in perinuclear/nuclear area in Y15-treated cells. The same was observed in DBTRG cells

## Figure S2.

Upper panel: Y15 decreases viability of U251 cell line in a dose-dependent manner. The treatment with Y15 was done in U251 cells for 24 hours and MTT assay was performed on the untreated and Y15-treated cells, as described in Materials and Methods. Bars show means  $\pm$  standard deviations. Lower panel: The combination of Y15 and temozolomide decreases more significantly viability of U251 cells than each agent alone. Bars show means  $\pm$  standard deviations. \*p value<0.05 versus untreated cells. \*\*p values for Y15+temozolomide versus Y15 and TMZ are shown.